Can buying a drug patent application be seen as a bid to prolong a monopoly? Amgen and an insurer are battling over the answer, and the FTC has weighed in

https://www.statnews.com/pharmalot/2026/08/31/pending-drug-patent-applications-amgen-carefirst/ By Ed SilvermanAug. 31, 2026 Pharmalot Columnist, Senior Writer